{
    "name": "teriparatide",
    "comment": "Rx",
    "other_names": [
        "Forteo",
        "parathyroid hormone",
        "Bonsity"
    ],
    "classes": [
        "Parathyroid Hormone Analogs"
    ],
    "source": "https://reference.medscape.com/drug/bonsity-forteo-teriparatide-342831",
    "pregnancy": {
        "common": [
            "There are no available data on use in pregnant women to evaluate for drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes; consider discontinuing drug when pregnancy is recognized"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "In animal reproduction studies, drug increased skeletal deviations and variations in mouse offspring at subcutaneous doses equivalent to more than 60 times recommended 20 mcg human daily dose (based on body surface area, mcg/m",
                    "), and produced mild growth retardation and reduced motor activity in rat offspring at subcutaneous doses equivalent to more than 120 times the human dose"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Not known whether teriparatide is excreted in human milk, affects human milk production, or has effects on breastfed infant; because of potential for osteosarcoma shown in animal studies, advise patients that breastfeeding is not recommended during therapy"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Transient orthostatic hypotension may occur with initial doses ",
                "May exacerbate urolithiasis; consider risk/benefit in patients with active or recent urolithiasis "
            ],
            "specific": [
                {
                    "type": "Osteosarcoma risk",
                    "description": [
                        "Avoid use in patients with with increased risk of osteosarcoma including those with",
                        "Open epiphyses (children, young adults)",
                        "Metabolic bone diseases including Paget disease, bone metastases, or history of skeletal malignancies",
                        "Prior external beam or implant radiation therapy involving the skeleton",
                        "Hereditary disorders predisposing to osteosarcoma"
                    ]
                },
                {
                    "type": "Hypercalcemia and cutaneous calcification",
                    "description": [
                        "Avoid in patients known to have an underlying hypercalcemic disorder",
                        "Discontinue in patients developing worsening of previously stable cutaneous calcification",
                        "Hypercalcemia may predispose patient to digoxin toxicity"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Digoxin",
                        "A single teriparatide dose did not alter the effect of digoxin on the systolic time interval ",
                        "Owing to teriparatide may transiently increase serum calcium, use with caution in patients taking digoxin",
                        "Consider potential onset of signs and symptoms of digitalis toxicity when used in patients receiving digoxin"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "digoxin",
            "description": {
                "common": "teriparatide increases toxicity of digoxin by Other (see comment). Use Caution/Monitor. \nComment: Transient hypercalcemia may predispose to digoxin toxicity (rare case reports)."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "alendronate",
            "description": {
                "common": "teriparatide, alendronate. Other (see comment). Minor/Significance Unknown. \nComment: No advantage to bone density with combined treatment."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "calcium acetate",
            "description": {
                "common": "teriparatide increases levels of calcium acetate by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "calcium carbonate",
            "description": {
                "common": "teriparatide increases levels of calcium carbonate by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "calcium chloride",
            "description": {
                "common": "teriparatide increases levels of calcium chloride by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "calcium citrate",
            "description": {
                "common": "teriparatide increases levels of calcium citrate by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "calcium gluconate",
            "description": {
                "common": "teriparatide increases levels of calcium gluconate by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "etidronate",
            "description": {
                "common": "teriparatide, etidronate. Other (see comment). Minor/Significance Unknown. \nComment: No advantage to bone density with combined treatment."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ibandronate",
            "description": {
                "common": "teriparatide, ibandronate. Other (see comment). Minor/Significance Unknown. \nComment: No advantage to bone density with combined treatment."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pamidronate",
            "description": {
                "common": "teriparatide, pamidronate. Other (see comment). Minor/Significance Unknown. \nComment: No advantage to bone density with combined treatment."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "risedronate",
            "description": {
                "common": "teriparatide, risedronate. Other (see comment). Minor/Significance Unknown. \nComment: No advantage to bone density with combined treatment."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tiludronate",
            "description": {
                "common": "teriparatide, tiludronate. Other (see comment). Minor/Significance Unknown. \nComment: No advantage to bone density with combined treatment."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "zoledronic acid",
            "description": {
                "common": "teriparatide, zoledronic acid. Other (see comment). Minor/Significance Unknown. \nComment: No advantage to bone density with combined treatment."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Cases of bone tumor and osteosarcoma reported rarely in the postmarketing period",
            "percent": "2"
        },
        {
            "name": "osteosarcoma surveillance safety studies in US were designed to obtain data on the incidence rate of osteosarcoma among teriparatide",
            "percent": "3"
        },
        {
            "name": "treated patients",
            "percent": "379,283"
        },
        {
            "name": "osteosarcoma cases were identified among",
            "percent": "153,316"
        },
        {
            "name": "of",
            "percent": null
        },
        {
            "name": "and none of",
            "percent": null
        },
        {
            "name": "teriparatide users",
            "percent": null
        },
        {
            "name": "Results suggest similar risk for osteosarcoma between teriparatide users and their comparators",
            "percent": null
        },
        {
            "name": "However",
            "percent": null
        },
        {
            "name": "interpretation of the results calls for caution owing to the limitations of the data sources which do not allow for complete measurement and control for confounders",
            "percent": null
        }
    ]
}